雷贝拉唑治疗十二指肠溃疡的临床观察

A Clinical Trial of Rabeprazole in the Treatment of Duodenal Ulcer

目的验证与评估雷贝拉唑治疗十二指肠溃疡的临床疗效和安全性。方法将活动期十二指肠溃疡患者随机分为雷贝拉唑(10 mg/d)治疗组和奥美拉唑(20 mg/d)对照组。服药4周后,胃镜观察溃疡愈合程度并观察有无不良反应出现。结果4周后治疗组和对照组溃疡愈合率分别为95.0%和93.6%,总有效率分别为99.0%和98.9%,两组无显著性差异(P>0.05),但治疗组腹痛消失更为迅速,治疗组第1天腹痛消失率为33.0%,而对照组为18.8%,有显著性差异(P<0.05)。结论雷贝拉唑和奥美拉唑治疗十二指肠溃疡均具有良好疗效,而雷贝拉唑第1天对腹痛的缓解作用更为明显,且无严重不良反应,值得临床上推广。

Objective To evaluate the effect and safety of Rabeprazole on patients with duodenal ulcer. Methods Patients with duodenal ulcer in active phase were randomly divided into group A （rabeprazole 10 mg/d） and group B （omeprozole 20 mg/d）. After 4 weeks treatment, the curative effect was detected by gastroscope and the side - effect was observed. Results After weeks of treatment, the healing rate of ulcer and total effective ratio in group A were 95.0% and 99.0% ,and in group B, they were 93.6 % and 98.9 %. There were no significance between group A and B （ P 〉0.05 ）. But the disappear rate of bellyache in group A was higher than that in group B （P〈0.05）, After 1 day treatment,in group A,33.0% patients＇ bellyache disappeared, but in group B, it＇ s 18.8 %. Conclusions The effects of rabeprazole and Omeprazole for duodenal ulcer is satisfactory. Rabeprazole is more effective cure for remitting abdominal pain and have little side - effect.